Aktis Oncology, Inc. - Common stock (AKTS) earnings

Quarterly and annual AKTS reports and results, each read against the price at its own news timestamp. Back to the AKTS overview →

10 measured AKTS earnings events.

DateHeadlineEvent5-minTo close
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026Press release-1.54%+4.00%
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026Press release+0.00%+7.70%
Form NT 10-Q Akoustis Technologies, For: Dec 31SEC filing · Form NT——
Form 10-Q Akoustis Technologies, For: Sep 30SEC filing · Form 10-Q+4.00%+7.00%
Form 10-K/A Akoustis Technologies, For: Jun 30SEC filing · Form 10-K-2.60%-3.12%
Form 10-K Akoustis Technologies, For: Jun 30SEC filing · Form 10-K-1.75%+11.73%
Form NT 10-K Akoustis Technologies, For: Jun 30SEC filing · Form NT-2.23%-15.20%
Form 10-Q Akoustis Technologies, For: Mar 31SEC filing · Form 10-Q-4.63%-22.46%
Form 10-Q Akoustis Technologies, For: Dec 31SEC filing · Form 10-Q-11.20%-12.51%
Form 10-Q Akoustis Technologies, For: Sep 30SEC filing · Form 10-Q-3.32%-6.05%
Get an email when AKTS moves on news →
Keep exploring

More AKTS: analyst actions → · SEC filings → · AKTS overview →

Other Technology names and their earnings

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.